McKesson Corporation $MCK Shares Sold by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments Holdings cut its McKesson stake by 10.2% in the third quarter, selling 22,164 shares and ending the period with 195,736 shares valued at about $175.9 million.
• McKesson beat quarterly estimates, posting adjusted EPS of $11.68 and revenue of $110.96 billion, up 7.5% year over year; the company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40.
• Institutional investors and hedge funds own 85.07% of McKesson. Analysts’ consensus is “Moderate Buy,” with an average price target of $1,026.18; recent insider sales were made under pre-arranged Rule 10b5-1 plans.

Allspring Global Investments Holdings LLC cut its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 10.2% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 195,736 shares of the company's stock after selling 22,164 shares during the period. Allspring Global Investments Holdings LLC owned about 0.17% of McKesson worth $175,931,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Nvwm LLC raised its position in shares of McKesson by 933.3% during the 3rd quarter. Nvwm LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 28 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in McKesson in the 2nd quarter worth about $27,000. Trellis Wealth Advisors LLC purchased a new stake in McKesson during the 3rd quarter worth approximately $32,000. Clearstead Trust LLC purchased a new stake in McKesson during the 2nd quarter worth approximately $37,000. Finally, GK Wealth Management LLC purchased a new stake in McKesson during the 3rd quarter worth approximately $38,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO B Jr sold 111 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the transaction, the chief accounting officer directly owned 521 shares of the company's stock, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of the business's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $995.80, for a total value of $796,640.00. Following the transaction, the executive vice president directly owned 5,423 shares of the company's stock, valued at approximately $5,400,223.40. This represents a 12.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,161 shares of company stock valued at $2,242,515 in the last quarter. Company insiders own 0.06% of the company's stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

McKesson Stock Down 0.0%

Shares of MCK stock opened at $1,060.79 on Monday. The firm has a 50 day moving average of $938.13 and a two-hundred day moving average of $868.12. The stock has a market capitalization of $122.48 billion, a PE ratio of 27.28, a P/E/G ratio of 1.97 and a beta of 0.27. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,121.50.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, topping analysts' consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The business had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. During the same quarter in the prior year, the company earned $9.86 earnings per share. The company's revenue was up 7.5% on a year-over-year basis. Analysts expect that McKesson Corporation will post 46.21 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson's dividend payout ratio (DPR) is presently 9.67%.

Wall Street Analyst Weigh In

Several research firms recently commented on MCK. Wells Fargo & Company increased their price objective on McKesson from $812.00 to $933.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 11th. Barclays lifted their target price on shares of McKesson from $925.00 to $1,000.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 19th. Leerink Partners lifted their target price on shares of McKesson from $1,070.00 to $1,200.00 and gave the stock an "outperform" rating in a research note on Thursday. Royal Bank Of Canada upped their target price on shares of McKesson from $845.00 to $965.00 and gave the stock a "sector perform" rating in a report on Thursday. Finally, Weiss Ratings upgraded shares of McKesson from a "buy (b-)" rating to a "buy (b)" rating in a research report on Friday, September 4th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, McKesson has a consensus rating of "Moderate Buy" and an average price target of $1,026.18.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.